Monte Rosa Therapeutics (GLUE) Other Accumulated Expenses (2020 - 2025)

Monte Rosa Therapeutics' Other Accumulated Expenses history runs 6 years deep, the most recent figure standing at $4.4 million for Q1 2025.

• In Q1 2025, Other Accumulated Expenses rose 104.68% year-over-year to $4.4 million; the TTM figure through Mar 2025 stood at $4.4 million (up 104.68% YoY), while the FY2024 annual figure was $3.4 million, up 100.72% from the prior year.
• Other Accumulated Expenses was $4.4 million for Q1 2025 at Monte Rosa Therapeutics, up from $3.4 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $5.0 million in Q4 2022 to a low of $840000.0 in Q4 2021.
• Historically, Other Accumulated Expenses has averaged $2.7 million across 5 years, with a median of $2.5 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Other Accumulated Expenses jumped 497.62% in 2022, then slumped 66.71% in 2023.
• A 5-year view of Other Accumulated Expenses shows it stood at $840000.0 in 2021, then surged by 497.62% to $5.0 million in 2022, then plunged by 66.71% to $1.7 million in 2023, then surged by 100.72% to $3.4 million in 2024, then jumped by 31.81% to $4.4 million in 2025.
• The last three Other Accumulated Expenses figures came in at $4.4 million (Q1 2025), $3.4 million (Q4 2024), and $1.3 million (Q3 2024), per Business Quant data.